ENYO Pharma Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
11
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$36.3M
- Investors
-
11
ENYO Pharma General Information
Description
Developer of small molecule therapeutics designed for conditions with unmet medical needs. The company offers therapeutics based on fibrinolytic and anti-inflammatory properties for rare kidney disease, Alport syndrome, and chronic liver diseases, enabling healthcare professionals to access treatment options for patients with these conditions.
Contact Information
Website
www.enyopharma.comCorporate Office
- WELLIO - SILEX 2
- 9-13 rue des Cuirassiers
- 69003 Lyon
- France
Corporate Office
- WELLIO - SILEX 2
- 9-13 rue des Cuirassiers
- 69003 Lyon
- France
ENYO Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC (Series C) | 12-Jun-2025 | $36.3M | Completed | Clinical Trials - Phase 2 | ||
| 6. Accelerator/Incubator | 08-Feb-2021 | Completed | Clinical Trials - Phase 2 | |||
| 5. Later Stage VC (Series B) | 02-Dec-2020 | Completed | Clinical Trials - Phase 2 | |||
| 4. Early Stage VC (Series B) | 04-Jun-2018 | Completed | Clinical Trials - Phase 2 | |||
| 3. Grant | 06-Dec-2016 | Completed | Pre-Clinical Trials | |||
| 2. Early Stage VC (Series A) | 03-Feb-2016 | $23.9M | $26.7M | Completed | Pre-Clinical Trials | |
| 1. Seed Round | 01-Jan-2015 | $2.76M | $2.76M | Completed | Pre-Clinical Trials |
ENYO Pharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A | ||||||||
| Ordinary Shares | 16,021 | $1.185910 | $166.18 | $166.18 | 1x | $166.18 |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
ENYO Pharma Comparisons
Industry
Financing
Details
ENYO Pharma Competitors (15)
One of ENYO Pharma’s 15 competitors is Genentech, a Formerly VC-backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Genentech | Formerly VC-backed | South San Francisco, CA | ||||
| Sanofi Pasteur | Corporation | Paris, France | ||||
| Merck & Co. | Corporation | Rahway, NJ | ||||
| Poxel | Formerly VC-backed | Lyon, France | ||||
| Biogen | Formerly VC-backed | Cambridge, MA |
ENYO Pharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
ENYO Pharma Patents
ENYO Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026002833-A1 | Ethanolamine salt of 4-chloro-5-[4-(2,6-dichlorophenyl)sulfonylpiperazin-1-yl]-1-benzofuran-2-carboxylic acid and various forms thereof | Pending | 24-Jun-2024 | ||
| EP-4743449-A1 | L-arginine salt of 4-chloro-5-[4-(2,6-dichlorophenyl)sulfonylpiperazin-1-yl]-1-benzofuran-2-carboxylic acid and various forms thereof | Pending | 13-Jul-2023 | ||
| WO-2025012422-A1 | L-arginine salt of 4-chloro-5-[4-(2,6-dichlorophenyl)sulfonylpiperazin-1-yl]-1-benzofuran-2-carboxylic acid and various forms thereof | Inactive | 13-Jul-2023 | ||
| AU-2024295030-A1 | L-lysine salt of 4-chloro-5-[4-(2,6-dichlorophenyl)sulfonylpiperazin-1-yl]-1-benzofuran-2-carboxylic acid and various forms thereof | Pending | 13-Jul-2023 | ||
| EP-4743450-A1 | L-lysine salt of 4-chloro-5-[4-(2,6-dichlorophenyl)sulfonylpiperazin-1-yl]-1-benzofuran-2-carboxylic acid and various forms thereof | Pending | 13-Jul-2023 | C07D307/85 |
ENYO Pharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
ENYO Pharma Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| CDP Venture Capital (Rome) | Venture Capital | Minority | ||
| Vesalius Biocapital Partners | Venture Capital | Minority | ||
| La French Tech | Accelerator/Incubator | |||
| Andera Partners | PE/Buyout | Minority | ||
| OrbiMed | Growth/Expansion | Minority |
ENYO Pharma FAQs
-
When was ENYO Pharma founded?
ENYO Pharma was founded in 2014.
-
Where is ENYO Pharma headquartered?
ENYO Pharma is headquartered in Lyon, France.
-
What is the size of ENYO Pharma?
ENYO Pharma has 11 total employees.
-
What industry is ENYO Pharma in?
ENYO Pharma’s primary industry is Drug Discovery.
-
Is ENYO Pharma a private or public company?
ENYO Pharma is a Private company.
-
What is ENYO Pharma’s current revenue?
The current revenue for ENYO Pharma is .
-
How much funding has ENYO Pharma raised over time?
ENYO Pharma has raised $122M.
-
Who are ENYO Pharma’s investors?
CDP Venture Capital (Rome), Vesalius Biocapital Partners, La French Tech, Andera Partners, and OrbiMed are 5 of 11 investors who have invested in ENYO Pharma.
-
Who are ENYO Pharma’s competitors?
Genentech, Sanofi Pasteur, Merck & Co., Poxel, and Biogen are some of the 15 competitors of ENYO Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
